구조모아 (StructureMoa)항암 chemical structure spider web
방문타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 다음 갱신 D-6 · 마지막 9월 2일
현재 선택: 1개 · 임상 갱신 필요 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | chimeric antigen receptor gene modified T cells (chimeric antigen receptor gene modified T cells) Nanjing IASO Biotechnology Co., Lt…·CD30 30 trials |
|---|---|
Overview Program | chimeric antigen receptor gene modified T cells |
Overview Company | Nanjing IASO Biotechnology Co., Ltd. |
Overview Modality | CGT |
Overview Target | CD30 |
Overview Indication | Lymphoma, B-Cell |
Overview Phase | PRECLINICAL |
Overview Status | RECRUITING |
Overview Content status | Standard Database |
Overview Data Confidence | Data Confidence · Medium |
Overview Development Signal | Development Signal · Watch |
Overview Approval status | Investigational |
Toxicology Major finding | Adoptive T-cell therapy for hematological malignancies using T cells gene-modified to express tumor antigen-specific receptors.. The functional properties of the adoptive immune response mediated by effector T lymphocytes are decisively regulated by their T-cell receptors (TCRs). Transfer of genes encoding target antigen-specific receptors enables polyclonal T cells to redirect toward cancer cells… |
Toxicology CRS | Reported |
Clinical Safety signal | Adoptive T-cell therapy for hematological malignancies using T cells gene-modified to express tumor antigen-specific receptors.. The functional properties of the adoptive immune response mediated by effector T lymphocytes are decisively regulated by their T-cell receptors (TCRs). Transfer of genes encoding target antigen-specific receptors enables polyclonal T cells to redirect toward cancer cells… |
Clinical Selected reported efficacy | ORR 92.9% |
Clinical Reported ORR | 92.9% |
Clinical Result source | ClinicalTrials.gov NCT03310619 |
Clinical Program phase | PRECLINICAL |
Clinical Trial ref | NCT03310619 |
타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 다음 갱신 D-6 · 마지막 9월 2일
현재 선택: 1개 · 임상 갱신 필요 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | chimeric antigen receptor gene modified T cells (chimeric antigen receptor gene modified T cells) Nanjing IASO Biotechnology Co., Lt…·CD30 30 trials |
|---|---|
Overview Program | chimeric antigen receptor gene modified T cells |
Overview Company | Nanjing IASO Biotechnology Co., Ltd. |
Overview Modality | CGT |
Overview Target | CD30 |
Overview Indication | Lymphoma, B-Cell |
Overview Phase | PRECLINICAL |
Overview Status | RECRUITING |
Overview Content status | Standard Database |
Overview Data Confidence | Data Confidence · Medium |
Overview Development Signal | Development Signal · Watch |
Overview Approval status | Investigational |
Toxicology Major finding | Adoptive T-cell therapy for hematological malignancies using T cells gene-modified to express tumor antigen-specific receptors.. The functional properties of the adoptive immune response mediated by effector T lymphocytes are decisively regulated by their T-cell receptors (TCRs). Transfer of genes encoding target antigen-specific receptors enables polyclonal T cells to redirect toward cancer cells… |
Toxicology CRS | Reported |
Clinical Safety signal | Adoptive T-cell therapy for hematological malignancies using T cells gene-modified to express tumor antigen-specific receptors.. The functional properties of the adoptive immune response mediated by effector T lymphocytes are decisively regulated by their T-cell receptors (TCRs). Transfer of genes encoding target antigen-specific receptors enables polyclonal T cells to redirect toward cancer cells… |
Clinical Selected reported efficacy | ORR 92.9% |
Clinical Reported ORR | 92.9% |
Clinical Result source | ClinicalTrials.gov NCT03310619 |
Clinical Program phase | PRECLINICAL |
Clinical Trial ref | NCT03310619 |
추천 비교
추천 비교